Removal of persisting isohaemagglutinins with Ig-Therasorb® immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haemotopoietic stem cell transplantation

Nephrology Dialysis Transplantation

Volumn 18, Issue 11, 2003, Pages 2405-2408

  Rabitsch, Werner ^a   Knöbl, Paul ^a   Greinix, Hildegard ^a   Prinz, Erika ^a   Kalhs, Peter ^a   Hörl, Walter H ^a   Derfler, Kurt ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Blood component removal; Blood group incompatibility; Haematopoetic stem cell transplantation; Red cell aplasia

Indexed keywords

CYCLOSPORIN; FLUDARABINE; HEMAGGLUTININ; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; APHERESIS; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD TRANSFUSION; CASE REPORT; ERYTHROCYTE APLASIA; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MORTALITY; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ABO BLOOD-GROUP SYSTEM; ADULT; BLOOD GROUP INCOMPATIBILITY; HEMAGGLUTININS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSORBENT TECHNIQUES; MALE; MIDDLE AGED; RED-CELL APLASIA, PURE;

EID: 0242288586     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg364     Document Type: Article

References (15)

1. Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or missmatched unreleted donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629
2. Lee JH, Lee JH, Choi SJ et al. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol 2003; 120: 702-710
3. Sniecinski IJ, Oien L, Petz LD, Blume KG. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation 1988; 45: 530-533
4. Nussbaumer W, Schwaighofer H, Gratwohl A et al. Transfusion of donor-type red cells as a single preparative treatment for bone marrow transplants with major ABO incompatibility. Transfusion 1995; 35: 592-595
5. Osterwalder B, Gratwohl A, Nissen C, Speck B. Immunoadsorption for removal of anti-A and anti-B blood group antibodies in ABO-incompatible bone marrow transplantation. Blut 1986; 53: 379-390
6. Bensinger W, Baker D, Buckner C et al. Immunoadsorption for removal of A and B blood-group antibodies. N Engl J Med 1981; 304: 160-162
7. Santamaria A, Sureda A, Martion R et al. Successful treatment of pur red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant 1997; 20: 1105-1107
8. Ohashi K, Akiyama H, Takamoto S et al. Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistent to erythropoietin. Bone Marrow Transplant 1994; 13: 335-336
9. Maschan AA, Skorobogatova EV, Balashov DN et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for aquired aplastic anemia. Bone Marrow Transplant 2002; 30: 405-407
10. Labar B, Bogdanic V, Memet D et al. Antilymphocyte globulin for treatment of pure red cell aplasia after major ABO incompatible marrow transplant. Bone Marrow Transplant 1992; 10: 471-472
11. Knöbl P, Derfler K. Immunologisch bedingte hämatologische Erkrankungen - indikationen für die Immunadsorption? In: Brunkhorst R ed. Klinische Immunadsorption. Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany; 1999
12. Widmann FK ed. Technical Manual, 9th Edn. American Association of Blood Banks, Arlington; 1995
13. Lapierre Y, Rigal D, Adam D et al. The gel test: a new way to detect red cell antigen-antibody reactions. Transfusion 1990; 30: 109-113
14. Knöbl P, Derfler K, Korninger L et al. Elimination of acquired factor VIII antibodies by extracorporeal antibody-based immunoadsorption (Ig-Therasorb). Thromb Haemost 1995; 74: 1035-1038
15. Jansen M, Schmaldienst S, Banyai S et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001; 112: 91-97